{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
mafodotin
to a specific field?
There is one exact (name or code) match for mafodotin
Status:
Investigational
Source:
USAN:MAFODOTIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mafodotin (mc-MMAF) is a hydrophilic non-cleavable antimicrotubule and antimitotic agent, monomethyl auristatin F (MMAF) derivative, having a maleimidocaproyl linker (mc linker), which is ready to conjugate to an antibody or other proteins or biopolymers. Antibody-drug conjugates having mafodotin such as Depatuxizumab mafodotin and Belantamab mafodotin have undergone clinical trials for the treatment of neoplasms.
Status:
Investigational
Source:
USAN:MAFODOTIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mafodotin (mc-MMAF) is a hydrophilic non-cleavable antimicrotubule and antimitotic agent, monomethyl auristatin F (MMAF) derivative, having a maleimidocaproyl linker (mc linker), which is ready to conjugate to an antibody or other proteins or biopolymers. Antibody-drug conjugates having mafodotin such as Depatuxizumab mafodotin and Belantamab mafodotin have undergone clinical trials for the treatment of neoplasms.
Status:
US Approved Rx
(2019)
Source:
BLA761073
(2019)
Source URL:
First approved in 1998
Source:
BLA103792
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mozistobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:caxmotabart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nesfrotamig [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:caxmotabart entudotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab brengitecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03455972: Phase 1/Phase 2 Interventional Unknown status Safety and Efficacy
(2018)
Source URL:
Class:
PROTEIN
